跳至主要内容
临床试验/CTRI/2016/12/007593
CTRI/2016/12/007593Other3 期

An open label, single-arm, multicentre study to evaluate safety and efficacy of Nutricharge Energy Drink in healthy human volunteers in India - Nutricharg Energy Drink

Trophic Wellness Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
Other
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a) Age group: 18 years - 40 years
  • b) Subjects in good physical condition and sound mental status.
  • c) In the judgment of the Principal Investigator, able to comply with protocol requirements.
  • d) Subjects passing all the screening tests
  • e) Subjects willing to sign written informed consent

排除标准

  • a) Pre Diabetic & Diabetic Subjects
  • b) Pre-hypertensive & Hypertensive subjects
  • c) Subjects addicted to alcohol, Drugs of Abuse or tobacco
  • d) Hypersensitivity to study product or any contents of the energy drink
  • e) Presence of any major illness such as cancer, heart disease, COPD, Asthma etc.
  • f) Subjects with current medical history of any major illness such as cancer, heart disease, COPD , Asthma etc. in the past
  • g) Subjects with history of any acute or chronic illness that may affect the patientâ??s participation in the study
  • h) Current use of vitamin or mineral supplements, nutritional supplements and or medical foods within 30 days prior to the beginning of the study and for the duration of the study.
  • i) Use of prescription medications and/or nonprescription medications for acute medical conditions, semi-acute medical conditions, and weight loss.
  • j) Subjects with acute illness or history of major or minor surgery in the past one year.
  • k) Female subjects who are currently pregnant and/or breast feeding
  • l) Subjects receiving any medical therapy for any illness.

研究者

发起方
Trophic Wellness Private Limited

相似试验

招募中
2 期
Study to evaluate the safety and efficacy of sacubitril valsartan under hemodialysisChronic heart failure
JPRN-jRCT1031230599Asanuma Katsuhiko32
招募中
1 期
Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpuraThrombotic Thrombocytopenic PurpuraMedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2022-001177-31-ATSanofi-Aventis Recherche & Développement64
招募中
1 期
Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpuraMedDRA version: 20.0Level: PTClassification code: 10043648Term: Thrombotic thrombocytopenic purpura Class: 100000004851Thrombotic Thrombocytopenic Purpura
CTIS2024-513262-19-00Sanofi-Aventis Recherche & Developpement71
进行中(未招募)
1 期
Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpuraMedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersThrombotic Thrombocytopenic Purpura
EUCTR2022-001177-31-DESanofi-Aventis Recherche & Développement64
尚未招募
3 期
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura
NL-OMON53928Sanofi BV2